Plaintiff No. 1 v. Defendants

In the high-stakes world of pharmaceuticals, a single molecule can be worth billions — and the moment a competitor begins manufacturing it without permission, the original patent owner's empire is under siege. This case is a textbook example of what happens when patent holders refuse to stay silent, and how Indian courts respond when the core of an innovation is being copied without consent. For any founder or IP professional, the lesson is clear: a patent is only as strong as your willingness to defend it.

The plaintiffs in this case were the rightful owners of two patents covering the compound LINAGLIPTIN and its derivatives — a significant pharmaceutical compound used in the treatment of type 2 diabetes. Linagliptin is not a minor molecule; it represents years of research, development, and regulatory investment. The defendants, however, allegedly began manufacturing LINAGLIPTIN tablets and selling them in the Indian market under the brand name BRLENTA-5, without obtaining any license, consent, or authorization from the patent holders. This unauthorized commercialization prompted the plaintiffs to approach the court seeking urgent relief, arguing that their exclusive statutory rights were being violated.

The plaintiffs argued that they held valid and subsisting patents over LINAGLIPTIN and its derivatives, and that the defendants' act of manufacturing and selling tablets containing this compound under the brand BRLENTA-5 constituted a clear infringement of their patent rights. They contended that no license or permission had been granted to the defendants, making the production and sale unlawful. The defendants, on the other hand, were served with notice in the matter, and the court proceeded to hear the matter on its merits. The central legal friction revolved around whether the defendants' actions amounted to unauthorized commercial exploitation of a patented compound, and whether the plaintiffs had made out a sufficient case to warrant immediate judicial intervention in the form of an injunction.

After hearing the matter on 11 February 2021, the court found that the plaintiffs had established a prima facie case in their favor. The court recognized that the plaintiffs, as owners of valid patents covering LINAGLIPTIN and its derivatives, held the exclusive statutory right to prevent third parties from exploiting their patented invention. The court ruled in favor of granting an interim order in favor of the plaintiffs, effectively restraining the defendants from continuing the alleged infringing manufacture and sale of LINAGLIPTIN tablets under the BRLENTA-5 brand during the pendency of the suit. The court's reasoning rested on the foundational principle that a patent grants its owner the exclusive right to prevent third parties from making, using, selling, or importing the patented product in India, as enshrined in Section 48 of the Patents Act, 1970.

For founders, startup leaders, and IP professionals, this case delivers a powerful reminder: a patent is not a passive document — it is an enforceable right that demands active defense. Under Section 48 of the Patents Act, 1970, a patent grants the exclusive right to prevent third parties from making, using, selling, or importing the patented product in India. If you discover that a competitor is manufacturing or selling your patented product without authorization, delay is your biggest enemy. Move swiftly, document the infringement, and seek interim injunctive relief before the market gets flooded with unauthorized copies. The cost of inaction is not just lost revenue — it is the erosion of the very exclusivity your patent was designed to protect.